Vimarsana
Biggest News Aggregation in the World

Page 39 - Webs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Webs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Webs Today - Breaking & Trending Today

KPIX CBS Evening News With Norah ODonnell June 4, 2024 01:41:00 - Vimarsana News

KPIX CBS Evening News With Norah ODonnell June 4, 2024 01:41:00

>> reporter: the cable giant's biggest stars plus fox corporation chair rupert murdoch could take the stand this week as the company battles a defamation lawsuit filed by dominion voting systems. >> whether it's dominion, ebs whatever the voting machine company is -- >> reporter: the lawsuit alleges that the network knowingly broadcast bogus claims that dominion was used to rig the election in favor of then candidate joe biden. >> what our next guest says is evidence of voter fraud. >> reporter: fox hosts and their frequent guests sydney powell, and rudy giuliani aired false claims following t...

AIB's Haven and EBS to increase selected variable mortgage rates – The Irish Times - Vimarsana News

AIB's Haven and EBS to increase selected variable mortgage rates – The Irish Times

Irish banks continue to trail European peers in passing on ECB rate hikes

Emergent BioSolutions (NYSE:EBS) Upgraded to "Buy" by Benchmark - Vimarsana News

Emergent BioSolutions (NYSE:EBS) Upgraded to "Buy" by Benchmark

Benchmark upgraded shares of Emergent BioSolutions (NYSE:EBS – Get Rating) from a hold rating to a buy rating in a report released on Monday morning, The Fly reports. Benchmark currently has $22.00 price target on the biopharmaceutical company’s stock. EBS has been the subject of a number of other research reports. TheStreet lowered Emergent BioSolutions […]

Emergent BioSolutions (NYSE:EBS) Upgraded to "Buy" by Benchmark - Vimarsana News

Emergent BioSolutions (NYSE:EBS) Upgraded to "Buy" by Benchmark

Benchmark upgraded shares of Emergent BioSolutions (NYSE:EBS – Get Rating) from a hold rating to a buy rating in a report released on Monday, The Fly reports. Benchmark currently has $22.00 target price on the biopharmaceutical company’s stock. Several other analysts have also weighed in on EBS. TheStreet lowered Emergent BioSolutions from a c- rating […]

Emergent Biosolutions Snags Upgrade After FDA Approves OTC Narcan - Vimarsana News

Emergent Biosolutions Snags Upgrade After FDA Approves OTC Narcan

The biotech plans to launch the over-the-counter product this summer, beating competitors to the punch.